Bio-Rad Laboratories Statistics Share Statistics Bio-Rad Laboratories has 27.06M
shares outstanding. The number of shares has increased by -2.51%
in one year.
Shares Outstanding 27.06M Shares Change (YoY) -2.51% Shares Change (QoQ) -3.11% Owned by Institutions (%) 69.15% Shares Floating 22.55M Failed to Deliver (FTD) Shares 1,757 FTD / Avg. Volume 0.54%
Short Selling Information The latest short interest is 1M, so 3.7% of the outstanding
shares have been sold short.
Short Interest 1M Short % of Shares Out 3.7% Short % of Float 5.19% Short Ratio (days to cover) 3.07
Valuation Ratios The PE ratio is -5.03 and the forward
PE ratio is 26.75.
Bio-Rad Laboratories's PEG ratio is
-0.03.
PE Ratio -5.03 Forward PE 26.75 PS Ratio 3.61 Forward PS 3 PB Ratio 1.41 P/FCF Ratio 34.82 PEG Ratio -0.03
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Bio-Rad Laboratories.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 6.48,
with a Debt / Equity ratio of 0.21.
Current Ratio 6.48 Quick Ratio 4.85 Debt / Equity 0.21 Debt / EBITDA -0.64 Debt / FCF 5.16 Interest Coverage 5.5
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $333.31K Profits Per Employee $-239.51K Employee Count 7,700 Asset Turnover 0.27 Inventory Turnover 1.56
Taxes Income Tax -498.3M Effective Tax Rate 21.27%
Stock Price Statistics The stock price has increased by -10.51% in the
last 52 weeks. The beta is 0.96, so Bio-Rad Laboratories's
price volatility has been higher than the market average.
Beta 0.96 52-Week Price Change -10.51% 50-Day Moving Average 267.56 200-Day Moving Average 278.2 Relative Strength Index (RSI) 60.55 Average Volume (20 Days) 323,470
Income Statement In the last 12 months, Bio-Rad Laboratories had revenue of 2.57B
and earned -1.84B
in profits. Earnings per share was -65.36.
Revenue 2.57B Gross Profit 1.38B Operating Income 269M Net Income -1.84B EBITDA -2.14B EBIT -2.29B Earnings Per Share (EPS) -65.36
Full Income Statement Balance Sheet The company has 488.1M in cash and 1.37B in
debt, giving a net cash position of -886.6M.
Cash & Cash Equivalents 488.1M Total Debt 1.37B Net Cash -886.6M Retained Earnings 7.42B Total Assets 10.21B Working Capital 2.26B
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was 455.2M
and capital expenditures -189M, giving a free cash flow of 266.2M.
Operating Cash Flow 455.2M Capital Expenditures -189M Free Cash Flow 266.2M FCF Per Share 9.44
Full Cash Flow Statement Margins Gross margin is 53.73%, with operating and profit margins of 10.48% and -71.86%.
Gross Margin 53.73% Operating Margin 10.48% Pretax Margin -91.27% Profit Margin -71.86% EBITDA Margin -83.46% EBIT Margin 10.48% FCF Margin 10.37%
Dividends & Yields BIO does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for BIO is $330,
which is 11.8% higher than the current price. The consensus rating is "Buy".
Price Target $330 Price Target Difference 11.8% Analyst Consensus Buy Analyst Count 4
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Mar 8, 2002. It was a
forward
split with a ratio of 2:1.
Last Split Date Mar 8, 2002 Split Type forward Split Ratio 2:1
Scores Altman Z-Score 3.29 Piotroski F-Score 6
